期刊文献+

冠状动脉粥样硬化管腔重构与斑块形态的320排CT研究

Coronary atherosclerotic vascular remodeling and plaque morphological 320-raw coronary computed tomography angiography
原文传递
导出
摘要 目的探讨320排冠状动脉CT造影(CCTA)血管重构和动脉斑块形态学的关系。方法纳入经320排CCTA检查的382例冠心病患者。男279例(73.0%),女103例(27.0%),年龄36~86岁,平均(58±11)岁。CCTA分析包括阳性重构、钙化斑块(CP)、非钙化斑块(NCP)、混合斑块(MP)、梗阻性斑块、偏心性斑块。通过手工测量血管横截面积定义重构指数(RI),RI=病变处血管横截面积/(病变处近端正常血管面积+远端血管面积)/2。RI〉1.10为PR,RI〈0.95为NR。RI=0.95~1.10为无重构。结果 382例1255个节段被发现存在动脉斑块,其中PR 121例(31.7%)148个节段(11.8%);NR 82例(21.4%)91个节段(7.3%)和无重构179例(46.9%)1016个节段(81.0%)。CP 159个节段(12.7%)、NCP 549个节段(43.7%)和MP 547个节段(43.6%);梗阻性病变194个节段(15.6%),非梗阻性病变1061个节段(84.4%);偏心性斑块1054个节段(84.0%),同心性斑块201个节段(16.0%)。单因素分析显示PR组MP、非梗阻性病变和偏心性斑块百分率高于NR和无重构组(75.0%、57.1%和40.8%,93.9%、82.4%和83.4%,99.3%、16.5%和87.8%,P值为0.034、0.041、0.044,均〈0.05)。在多因素Cox比例风险回归模型分析中,只有偏心性斑块是发生PR的独立因素。结论 CCTA表现为MP、非梗阻性斑块和偏心性斑块,PR发生率高,而偏心性斑块是发生PR的独立因素。 Objective To investigate relation of coronary atherosclerotic vascular remodeling and plaque morphological 320-raw coronary computed tomography angiography(CCTA) in patients with coronary artery diseases. Methods This study consisted of 382 consecutive patients with coronary artery diseases who underwent 320-raw CCTA examination, male 279 cases(73.0%), female 103 cases(27.0%), age 36-86(58±11)years. The CCTA analysis included the presence of positive remodeling (PR), calcified plaque(CP), non-calcified plaque(NCP), mixed plaque(MP), obstructive plaque, and eccentric plaque. The manual inspection was used to define the remodeling index(RI) in the axial cross section area. RI=the axial cross section area at the plaque site/the axial cross section area proximal to the plaque site in a normal-appearing vessel segment+the axial cross section area distal to the plaque site in a normal-appearing vessel segment/2.The PR was defined by a RI〉 1.10, The NR was defined by a RI〈0.95, and non-remodeling was defined by a RI=0.95-1.10. Results Of the 382 patients, the 1255 plaques were observed, including PR in 121 cases (31.7%), 148 segments(11.8%), NR in 82 cases(21.4%), 91 segments(7.3%) and non-remodeling in 179 cases (46.9%), 1016 segments(81.0%), CP in 159 segments(12.7%), NCP in 549 segments (43.7%) and MP in 547 segments(43.6%), obstructive plaque in 194 segments(15.6%), non-obstructive plaque in 1061 segments(84.4%); eccentric plaque in 1054 segments(84.0%), concentric plaque in 201 segments(16.0%). Segment-based single factor analysis showed that MP, non-obstructive plaque and eccentric plaque had a higher prevalence with PR compared with NR and non-remodeling(75.0% vs. 57.1% vs. 40.8%; 93.9% vs. 82:4% vs. 83.4%; 99.3% vs. 16.5% vs. 87.8%; P=0.034, 0.041, 0.044, respectively). Segment-based Cox proportional ha2ards models analysis showed that only eccenlricifiveplaquewere independent predictive factors for PR(HR=2.15, 95% CI: 0.81-6.70, P〈0.05). Conclusion The present study demonstrated that the MP, non-obstructive plaque and eccentric plaque had a higher prevalence with PR compared with NR and non-remodeling, then only eccentric plaque were independent predictive factors for PR.
机构地区 解放军第
出处 《中华临床医师杂志(电子版)》 CAS 2013年第20期47-50,共4页 Chinese Journal of Clinicians(Electronic Edition)
关键词 冠心病 体层摄影术 X线计算机 阳性重构 Coronary disease Tomography, X-ray computed Positive remodeling
  • 相关文献

参考文献46

  • 1Glagov S,Weisenberg E,Zarins CK. Compensatory enlargement of human atherosclerotic coronary arteries[J].{H}New England Journal of Medicine,1987.1371-1375.
  • 2Pasterkamp G,Wensing PJ,Post MJ. Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries[J].{H}CIRCULATION,1995.1444-1449.
  • 3Matsuo Y,Takumi T,Mathew V. Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems[J].{H}ATHEROSCLEROSIS,2012.365-371.
  • 4Nozue T,Yamamoto S,Tohyama S. Comparison of arterial remodeling and changes in plaque composition between patients with progression versus regression of coronary atherosclerosis during statin therapy(from the TRUTH study)[J].{H}American Journal of Cardiology,2012.1247-1253.
  • 5Pryor DB,Shaw L,McCants CB. Value of the history and physical in identifying patients at increased risk for coronary artery disease[J].{H}ANNALS OF INTERNAL MEDICINE,1993.81-90.
  • 6Mat D,Scheffel H,Leschka S. Dual-source CT coronary angiography:image quality,mean heart rate,and heart rate variability[J].{H}AJR American Journal of Roentgenology,2007.567-573.
  • 7中华放射学杂志心脏冠状动脉多排 CT 临床应用协作组.心脏冠状动脉多排CT临床应用专家共识[J]{H}中华放射学杂志,20119-17.
  • 8Cheng VY,Wolak A,Gutstein A. Low-density lipoprotein and noncalcified coronary plaque composition in patients with newly diagnosed coronary artery disease on computed tomographic angiography[J].{H}American Journal of Cardiology,2010.761-766.
  • 9Imazeki T,Sato Y,Inoue F. Evaluation of coronary artery remodeling in patients with acute coronary syndrome and stable angina by multislice computed tomography[J].{H}CIRCULATION JOURNAL,2004.1045-1050.
  • 10Varnava AM,Mills PG,Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability[J].{H}CIRCULATION,2002.939-943.

二级参考文献30

  • 1Rosell R,Lord R V,Taron M,et al.DNA repair and cisplatin resistance in non-small-cell lung cancer[J].Lung cancer,2002,38(3):217-227.
  • 2Sarries C,Haura E B,Roig B,et al.Pharmacogenomics strategies for developing customized chemotherapy in non-small cell lung cancer[J].Pharmacogenomics,2002,3(6):763-780.
  • 3Shirota Y,Stoehlmacher J,Brabender J,et al.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracilChemotherapy[J].Clin Oncol,2001,19(23):4298-4304.
  • 4Lord R V N,Brabender J,Gandara D,et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer[J].Clin Cancer Res,2002,8:2286-2291.
  • 5Rosell R,Pifarre A,Monzo M,et al.Reduced survival in patients with stage-Ⅰ non-small-cell lung cancer associated with DNA-replication errore[J].Int J Cancer,1997,74(3):330-333.
  • 6Bepler G,Gautam A,Mclntyre L N,et al.Prognostic significance of molecular genetic aberration on chromosome segment 11p15.5 in non-small cell lung cancer[J].J Clin Oncol,2002,20(5):1353-1360.
  • 7Rosell R,Cobo M,Isla D,et al.ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin(cis) or gemcitabine (gem)in stageⅣ non-small-cell Lung cancer(N SCLC) patients[J].J Clin Oncol,2005,23(suppl 1):7002.
  • 8Olaussen K A,Ariane D,Fouret P,et al.DNA repair by ERCCl in Non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,355(10):983-991.
  • 9Gautam A,Li Z R,Bepler G.RRM1-induced metastasis suppression through PTEN-regulated pathways[J].Oncogene,2003,22(14):2135-2142.
  • 10Bepler G,Shama S,CantorA,et al.RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer[J].J Ciln Oncol,2004,22(10):1878-1885.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部